Evidence Table D-11. Duration of delirium outcomes for studies comparing interventions to prevent development of delirium

| Author, year | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Mean (SD) days, intervention group | Mean (SD) days, control group | Mean between-group difference (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |
| Al-Qadheeb, 2016[2](#_ENREF_2) | MV patients with subsyndromal delirium | Haloperidol (Planned dose: 1mg), 34 | Placebo (Planned dose: 5% dextrose), 34 | Intravenous | Duration of first episode of delirium (d) | 1.67 (0.8) | 3 (1.6) | -1.33 (-1.93 to -0.73) |
| Fukata, 2014[3](#_ENREF_3) | Delirium after abdominal or orthopedic surgery in elderly patients | Haloperidol (Planned dose: 2.5mg), 59 | Placebo, 60 | Intravenous | Persistence of delirium | 1.38 (0.9) | 1.1 (0.8) | 0.28 (-0.03 to 0.59) |
| Girard, 2010[4](#_ENREF_4) | > 18 years MV medical and surgical ICU patients | Haloperidol (Planned dose: 5 Median dose: 15 (10.8-17), 35 | Placebo (Planned dose: 5ml), 36 | Oral | Delirium days | 4.33 (3.9) | 4 (3.2) | 0.33 (-1.33 to 1.99) |
| Kalisvaart, 2005[6](#_ENREF_6) | Acute or elective hip surgery patients ≥ 70 years, at risk of delirium: MMSE between less than or equal to 24; dehydration=BUN/creatinine> or = to 18, low visual acuity and/or increased severity of illness on APACHE II of 16 or greater. | Haloperidol (Planned dose: 0.5mg), 32 | Placebo (Not applicable), 36 | Oral | Delirium duration, days | 5.4 (4.9) | 11.8 (7.5) | -6.4 (-9.41 to -3.39) |

| Author, year | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Mean (SD) days, intervention group | Mean (SD) days, control group | Mean between-group difference (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Khan, 2018[8](#_ENREF_8) | English speaking individuals undergoing thoracic surgery | Haloperidol (Planned dose: 0.5mg, Planned duration: 4 days (11 doses total)), 68 | Placebo (Planned dose: NR, Planned duration: 4 days (11 doses total)), 67 | Intravenous | Delirium days | Median: 1 (IQR 1 to 2) | Median: 1 (IQR 1 to 2) |  p=0.71 |
| Page, 2013[10](#_ENREF_10) | ICU patients needing MV within 72 hours of admission were enrolled | Haloperidol (Planned dose: 2.5mg), 71 | Placebo (Planned dose: 0.5ml), 70 | Intravenous | Days in delirium | 5 (4.7) | 4.67 (5.6) | 0.33 (-1.38 to 2.04) |
| Page, 2013[10](#_ENREF_10) | ICU patients needing MV within 72 hours of admission were enrolled | Haloperidol (Planned dose: 2.5mg), 71 | Placebo (Planned dose: 0.5ml), 70 | Intravenous | Days in delirium | 5.67 (6.3) | 5 (6.3) | 0.67 (-1.41 to 2.75) |
| Schrijver, 2018[12](#_ENREF_12) | Medical and surgical patients | Haloperidol (Planned dose: 1mg), 23 | Placebo, 18 | Oral | Days | 3.67 (2.4) | 3.33 (4) | 0.34 (-1.68 to 2.36) |

| Author, year | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Mean (SD) days, intervention group | Mean (SD) days, control group | Mean between-group difference (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Second-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |
| Girard, 2010[4](#_ENREF_4) | > 18 years MV medical and surgical ICU patients | Ziprasidone (Planned dose: 40 Median dose: 113mg (81-140mg)), 30 | Placebo (Planned dose: 5ml), 36 | Oral | Delirium days | 4.67 (4.7) | 4 (3.2) | 0.67 (-1.27 to 2.61) |
| Hakim, 2012[5](#_ENREF_5) | Patients 65 years or older experiencing subsyndromal delirium after on-pump cardiac surgery | Risperidone (Planned dose: 0.5mg),  | Placebo (Planned dose: given every 12 hours),  | Oral | Failure to treat subsyndromal delirium with risperidone |  |  |  Subhazard ratio: 3.83 (SE 1.67) (95% CI: 1.63 to 8.98), p=0.002 |
| Hakim, 2012[5](#_ENREF_5) | Patients 65 years or older experiencing subsyndromal delirium after on-pump cardiac surgery | Risperidone (Planned dose: 0.5mg), 7 | Placebo (Planned dose: given every 12 hours), 17 | Oral | Duration of clinical delirium, for affected patients, days | 3 (1.6) | 3.33 (0.8) | -0.33 (-1.34 to 0.68) |
| Larsen, 2010[9](#_ENREF_9) | Post-operative elderly joint replacement surgery patients | Olanzapine (Planned dose: 5mg), 28 | Placebo (Planned dose: 5mg), 82 | Oral |  Duration of delirium | 2.2 (1.3) | 1.6 (0.7) | 0.6 (0.21 to 0.99) |
|  First-generation antipsychotic vs. second-generation antipsychotic |   |   |   |   |   |   |   |   |
| Girard, 2010[4](#_ENREF_4) | > 18 years MV medical and surgical ICU patients | Ziprasidone (Planned dose: 40 Median dose: 113mg (81-140mg)), 30 | Haloperidol (Planned dose: 5 Median dose: 15mg (10.8-17mg)), 35 | Oral  | Delirium days | 4.67 (4.7) | 4.33 (4) | 0.34 (-1.78 to 2.46) |

CI=confidence interval; d=days; ICU=intensive care unit; mg=milligram; ml=millimeter; MV=mechanical ventilation; N=sample size; SD=standard deviation; SE=standard error